Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study

Clinical Microbiology and Infection

Volumn 22, Issue 12, 2016, Pages 990-995

  Gergely Szabo, B ^a,b   Kadar, B ^a,b   Szidonia Lenart, K ^a,b   Dezsenyi, B ^a,b   Kunovszki, P ^c   Fried, K ^a   Kamotsay, K ^a   Nikolova, R ^a   Prinz, G ^a  

^a Joined Saint Stephan and Saint Ladislaus Hospital Clinic   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Clostridium difficile; Colitis; diarrhoea; nosocomial infection; tigecycline

Indexed keywords

METRONIDAZOLE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HOSPITAL MORTALITY; HUMAN; ILEUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEPSIS; SEVERE CLOSTRIDIUM DIFFICILE INFECTION; TOXIC MEGACOLON; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTRAABDOMINAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLECTOMY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MIDDLE AGED; MINOCYCLINE; RECURRENCE; RETROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84992390986     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.08.017     Document Type: Article

References (23)

1. [1] Stuart, H.C., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
2. [2] Debast, S., Bauer, M., Kuijper, E., European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20 (2014), 1–26.
3. [3] Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 quiz 499.
4. [4] Goorhuis, A., Bakker, D., Corver, J., Debast, S.B., Harmanus, C., Notermans, D.W., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47 (2008), 1162–1170.
5. [5] Kuijper, E.J., Wilcox, M.H., Editorial Commentary: decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?. Clin Infect Dis 47 (2008), 63–65.
6. [6] Bartlett, J., Narrative Review: the new epidemic of Clostridium difficile–associated enteric disease. Ann Intern Med 145 (2006), 758–764.
7. [7] Hawser, S., Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 35 (2010), 96–97.
8. [8] Rashid, M.U., Lozano, H.M., Weintraub, A., Nord, C.E., In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 20 (2013), 32–35.
9. [9] Noren, T., Alriksson, I., Akerlund, T., Burman, L., Unemo, M., In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 16 (2010), 1104–1110.
10. [10] Jump, R.L.P., Li, Y., Pultz, M.J., Kypriotakis, G., Donskey, C.J., Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 55 (2011), 546–549.
11. [11] Baines, S.D., Saxton, K., Freeman, J., Wilcox, M.H., Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 58 (2006), 1062–1065.
12. [12] Kundrapu, S., Hurless, K., Sunkesula, V.C.K., Tomas, M., Donskey, C.J., Tigecycline exhibits inhibitory activity against Clostridium difficile in the intestinal tract of hospitalised patients. Int J Antimicrob Agents 45 (2015), 424–426.
13. [13] Fantin, F., Manica, A., Soldani, F., Bissoli, L., Zivelonghi, A., Zamboni, M., Use of tigecycline in elderly patients for Clostridium difficile infection. Geriatr Gerontol Int 15 (2015), 230–231.
14. [14] Thomas, A., Khan, F., Uddin, N., Wallace, M.R., Tigecycline for severe Clostridium difficile infection. Int J Infect Dis 26 (2014), 171–172.
15. [15] Britt, N.S., Steed, M.E., Potter, E.M., Clough, L.A., Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infect Dis Ther 3 (2014), 321–331.
16. [16] Larson, K., Belliveau, P., Spooner, L., Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 45 (2011), 1005–1010.
17. [17] Lao, D., Chiang, T., Gomez, E., Refractory Clostridium difficile Infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep Med 2012 (2012), 1–3.
18. [18] Herpers, B.L., Vlaminckx, B., Burkhardt, O., Blom, H., Biemond-Moeniralam, H.S., Hornef, M., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48 (2009), 1732–1735.
19. [19] Charlson, M., Pompei, P., Ales, K., MacKenzie, C., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
20. [20] Lewis, S., Heaton, K., Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32 (1997), 920–924.
21. [21] Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29 (2003), 530–538.
22. [22] Miller, M.A., Louie, T., Mullane, K., Weiss, K., Lentnek, A., Golan, Y., et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis, 13, 2013, 148.
23. [23] Di Bella, S., Nisii, C., Petrosillo, N., Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. Int J Antimicrob Agents 46 (2015), 8–12.